TY  - JOUR
AU  - Hidalgo-Ríos, Samuel
AU  - Carrillo-García, Jaime
AU  - Moura, David S
AU  - Stacchiotti, Silvia
AU  - López-Pousa, Antonio
AU  - Redondo, Andrés
AU  - Italiano, Antoine
AU  - Gutiérrez, Antonio
AU  - Grignani, Giovanni
AU  - Hindi, Nadia
AU  - López-Guerrero, José-Antonio
AU  - Muro, Xavier García Del
AU  - Trufero, Javier Martínez
AU  - Palmerini, Emanuela
AU  - García, Ana Sebio
AU  - Bernabeu, Daniel
AU  - Le Cesne, Axel
AU  - Casali, Paolo Giovanni
AU  - Blay, Jean-Yves
AU  - Cruz Jurado, Josefina
AU  - Martin-Broto, Javier
PY  - 2022
DO  - 10.3390/cancers14174186
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/20915
T2  - Cancers
AB  - Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with...
LA  - en
KW  - NLR
KW  - PLR
KW  - RDW
KW  - inflammation
KW  - neutrophil/lymphocyte ratio
KW  - pazopanib
KW  - platelet/lymphocyte
KW  - red cell distribution width
KW  - solitary fibrous tumour
TI  - Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib.
TY  - research article
VL  - 14
ER  -